Last updated: April 24, 2026

Application No. 19/406,929

Untitled Application

Unknown

Filed

1600

Examiner

RZECZYCKI, PHILLIP MATTHEW

Art Unit

1625

Tech Center

Bristol-Myers Squibb Company

Assignee

Bristol-Myers Squibb Company

OA Round

1 (Non-Final)

This examiner grants 59% of cases after interview

— +42.8% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 93 resolved cases, 2023–2026

Examiner Intelligence

RZECZYCKI, PHILLIP MATTHEW View full profile →

Grants 59% of resolved cases

Career Allow Rate

55 granted / 93 resolved

-0.9% vs TC avg

Strong +43% interview lift

Without

With

+42.8%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

60 currently pending

Career history

153

Total Applications

across all art units

Statute-Specific Performance

§101

3.0%

-37.0% vs TC avg

§103

32.3%

-7.7% vs TC avg

§102

16.7%

-23.3% vs TC avg

§112

30.7%

-9.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 93 resolved cases

Prosecution Timeline

1600

Application Filed

Feb 23, 2026

Non-Final Rejection

Apr 08, 2026

Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

17/916,645

Patent 12605355

HA-PACLITAXEL CONJUGATE FOR TREATMENT OF MESOTHELIOMA

2y 5m to grant Granted Apr 21, 2026

17/767,119

Patent 12589103

ANTIMICROBIAL AND ANTIVIRAL EFFECTS OF C2-C7 ALKYL BORONIC ACIDS

2y 5m to grant Granted Mar 31, 2026

17/782,117

Patent 12590070

ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE

2y 5m to grant Granted Mar 31, 2026

17/783,863

Patent 12570607

COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF

2y 5m to grant Granted Mar 10, 2026

17/632,612

Patent 12564638

EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF

2y 5m to grant Granted Mar 03, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.

Prosecution Projections

1-2

Expected OA Rounds

59%

Grant Probability

99%

With Interview (+42.8%)

3y 7m

Median Time to Grant

Low

PTA Risk

Based on 93 resolved cases by this examiner. Grant probability derived from career allow rate.